Biosimulation Market - https://www.grandviewresearch.com/industry-analysis/biosimulation-industry
Colding-Jorgensen, "
Biosimulation of peptides and proteins," in Pharmaceutical Formulation Development of Peptides and Proteins, L.
FDA in 2015, more than 90 percent leveraged
biosimulation to inform that drug label.
1 December 2015 - US-based
biosimulation technology-enabled drug development company Certara has acquired XenologiQ, a UK-based quantitative systems pharmacology consultancy, the company said.
[ClickPress, Thu Aug 20 2015]
Biosimulation Market by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), Application (Drug Discovery & Development, Preclinical, Clinical Trial) & by End Users - Global Forecast to 2020
is employed by
BioSimulation Consulting Inc., Newark, DE.
Gene Network Sciences is a leader in
biosimulation with its ability to derive molecular mechanisms of drugs and diseases directly from molecular profiling and clinical data.
Biosimulation involves the use of computational models for providing dynamic and quantitative description of relevant biological, pathological, and pharmacokinetic processes in drug discovery and development.
And it is easy to imagine the convergence of
biosimulation and telesurgery in the near future.